Shares of Becton, Dickinson and Company (BDX) traded 1.04 points or 0.59% higher at $178.33.The total intraday money flow for the shares came in at a disappointing $(-4.35) million. The total upticks amounted to $61.97 million and the total downticks were approximately $66.32 million, with the up/down ratio of 0.93. On a different note, the shares have seen 1.74% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $5.82 million in upticks and an outflow of $12.66 million in downticks. The up/down ratio for the block was found to be 0.46. The net money flow for the block transaction was $(-6.84) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Becton, Dickinson and Company rose by 4.31% in the last five trading days and 8.11% for the last 4 weeks. Becton, Dickinson and Company is up 7.06% in the last 3-month period. Year-to-Date the stock performance stands at 8.11%. Becton, Dickinson and Company (NYSE:BDX) rose 0.95% or 1.68 points on Wednesday and made its way into the gainers of the day. After trading began at $175.88 the stock was seen hitting $179.14 as a peak level and $174.35 as the lowest level. The stock ended up at $178.97. The daily volume was measured at 1,716,115 shares. The 52-week high of the share price is $181.755 and the 52-week low is $129.5. The company has a market cap of $41,384 million.
Company has reported several Insider transactions to the SEC, on Dec 16, 2016, John E Gallagher (VP, Corp Finance and Treasurer) sold 1,793 shares at 168.82 per share price.On Dec 6, 2016, Stephen Sichak (Executive Vice President) sold 2,632 shares at 164.44 per share price.On Sep 7, 2016, Linda M Tharby (Executive Vice President) sold 11,704 shares at 177.34 per share price.
Becton Dickinson and Co Last issued its quarterly earnings results on Nov 3, 2016. The company reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.05. Analyst had a consensus of $2.07. The company had revenue of $3231.00 million for the quarter, compared to analysts expectations of $3218.89 million. The companys revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.94 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Becton Dickinson and Co was Downgraded by Raymond James to Outperform on Jan 5, 2017. Becton Dickinson and Co was Downgraded by JP Morgan to Neutral on Jan 3, 2017.
Becton, Dickinson and Co. is engaged principally in the manufacture and sale of a broad line of supplies, devices and systems used by health care professionals, medical research institutions and the general public. BDs operations consist of three worldwide business segments: Medical Systems, Biosciences, and Preanalytical Solutions.